VOYAGER THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.845 USD | +2.95% |
|
+4.16% | -6.58% |
| 02/04 | Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer | CI |
| 02/04 | Voyager Therapeutics, Inc. Announces CFO Changes | CI |
Chart calendar Voyager Therapeutics, Inc.
7e17058f.J_3TwHbNxqzV8_mHIsEK-STSCTAHYsaE48cHtEIQJ5c.VZykpT2Vrcisgp6ySpVEplyqXWgzA5nTsvNw1TomU91PtYGEFf2W-KeboA~07ea8255c4df2ead6367f9edc2dbfb89
Upcoming events on Voyager Therapeutics, Inc.
Past events on Voyager Therapeutics, Inc.
| 05/03/2024 | Alzheimer and Parkinson Diseases and Related Neurological Disorders International Conference |
| 29/02/2024 03:00 am | Q4 2023 Earnings Call |
| 29/02/2024 02:31 am | Q4 2023 Earnings Release |
| 14/02/2024 09:50 pm | Oppenheimer Healthcare Life Sciences Conference |
| 10/01/2024 11:15 pm | JPMorgan Healthcare Conference |
| 07/11/2023 03:00 am | Q3 2023 Earnings Call |
| 07/11/2023 02:31 am | Q3 2023 Earnings Release |
| 03/10/2023 03:00 am | Chardan Genetic Medicines Conference |
| 13/09/2023 12:05 am | Baird Global Healthcare Conference |
| 06/09/2023 07:00 pm | Wells Fargo Healthcare Conference |
| 10/08/2023 08:00 pm | Canaccord Genuity Growth Conference |
| 03/08/2023 06:00 pm | Q2 2023 Earnings Call |
| 03/08/2023 04:30 pm | Q2 2023 Earnings Release |
| 09/06/2023 01:00 am | Jefferies Global Healthcare Conference |
| 06/06/2023 06:30 pm | Annual General Meeting |
| 20/05/2023 12:30 am | American Society of Gene Cell Therapy Meeting - Poster No 1626 |
| 20/05/2023 12:30 am | American Society of Gene Cell Therapy Meeting - Poster No 1393 |
| 19/05/2023 02:45 am | American Society of Gene and Cell Therapy Conference - Directed Evolution of an AAV9 |
| 18/05/2023 12:30 am | American Society of Gene Cell Therapy Meeting - Poster No 394 |
| 18/05/2023 12:30 am | American Society of Gene Cell Therapy Meeting - Poster No 695 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 104 84,1 24.2% | 171 180 -5.13% | 37,4 27,5 36.28% | 40,9 46,2 -11.44% | 250 181 38.46% | 38,8 |
|
EBITDA Million USD | Released Forecast Spread | -48,9 -57,9 15.5% | 31,2 46,9 -33.54% | -68,5 -86,2 20.63% | -44,6 -35,3 -26.57% | 126 97,5 29.7% | -96,7 |
|
EBIT Million USD | Released Forecast Spread | -51,7 -70,1 26.23% | 27,4 28,0 -2.34% | -73,6 -94,4 22.03% | -50,8 -48,0 -5.97% | 122 54,6 123.48% | -111 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -43,6 -60,1 27.43% | 36,7 30,0 22.51% | -71,2 -92,1 22.66% | -46,4 -44,8 -3.59% | 134 65,8 103.17% | -98,4 |
|
Net income Million USD | Released Forecast Spread | -43,6 -60,1 27.43% | 36,7 30,0 22.51% | -71,2 -92,1 22.66% | -46,4 -44,8 -3.62% | 132 63,3 109.08% | -98,4 |
|
EPS USD | Released Forecast Spread | -1,21 -1,70 28.72% | 0,98 0,84 17.05% | -1,89 -2,36 19.8% | -1,21 -1,16 -4.44% | 2,97 1,44 106.66% | -1,80 |
| Announcement Date | 03/03/20 | 25/02/21 | 08/03/22 | 07/03/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 28,1 14,5 92.99% | 0,66 12,7 -94.82% | 0,71 5,17 -86.22% | 41,1 9,03 355.17% | -1,55 3,73 -141.54% | 150 52,5 186.63% | 4,85 1,60 202.99% | 4,61 2,91 58.69% | 90,1 20,6 336.4% | 9,48 | 7,59 | 7,65 | 8,43 | 8,70 |
|
EBITDA Million USD | Released Forecast Spread | 7,18 -10,8 166.64% | -18,5 -17,0 -9.05% | -18,2 -12,3 -48.27% | 15,8 -8,50 285.68% | -23,7 -14,3 -65.76% | 124 -17,8 796.4% | -24,3 -25,0 2.64% | -28,6 -29,0 1.51% | 55,4 -16,5 435.75% | -23,7 | -23,1 | -23,7 | -23,5 | |
|
EBIT Million USD | Released Forecast Spread | 5,70 -16,8 133.93% | -21,4 -10,9 -95.57% | -19,4 -18,4 -5.37% | 14,4 -12,2 218.53% | -24,6 -21,7 -13.27% | 123 25,8 376.57% | -25,4 -25,9 1.67% | -29,5 -27,5 -7.41% | 54,1 -13,4 504.23% | -26,8 | -29,3 | -30,8 | -31,5 | -43,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 5,71 -16,9 133.85% | -21,3 -10,9 -95% | -19,1 -18,5 -3.31% | 17,6 -12,2 243.93% | -23,6 -21,5 -9.85% | 125 25,9 380.75% | -22,1 -24,7 10.48% | -26,1 -25,4 -2.57% | 57,2 -10,7 634.72% | -23,8 | -25,9 | -27,5 | -28,3 | -40,1 |
|
Net income Million USD | Released Forecast Spread | 5,71 -16,9 133.86% | -21,3 -10,9 -95% | -19,1 -18,5 -3.31% | 17,6 -12,2 243.93% | -23,6 -21,5 -9.93% | 124 25,9 378.04% | -22,2 -24,7 10.24% | -25,9 -25,4 -1.88% | 56,4 -12,8 541.07% | -23,8 | -25,9 | -27,5 | -28,3 | -40,1 |
|
EPS USD | Released Forecast Spread | 0,15 -0,32 147.37% | -0,56 -0,37 -50.84% | -0,50 -0,48 -4.79% | 0,45 -0,34 233.33% | -0,61 -0,55 -11.49% | 2,94 1,04 183.78% | -0,51 -0,57 10.3% | -0,59 -0,58 -1.47% | 1,25 -0,29 533.17% | -0,44 | -0,47 | -0,49 | -0,51 | -0,59 |
| Announcement Date | 08/03/22 | 04/05/22 | 04/08/22 | 08/11/22 | 07/03/23 | 09/05/23 | 03/08/23 | 06/11/23 | 28/02/24 | - | - | - | - | - |
| Today 01:35 am | QIAGEN N.V.: Q1 2024 Earnings Release |
| 30/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 04:00 pm | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 04:00 pm | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 04:30 pm | ALKERMES PLC: Q1 2024 Earnings Release |
| 02/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Voyager Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- VYGR Stock
- Calendar Voyager Therapeutics, Inc.
